Abstract
We used the National Cancer Database (NCDB) to investigate the utilization and effectiveness of high-dose thoracic radiotherapy (RT) with systemic therapy (ST), compared to low-dose RT with ST, or ST alone in patients with metastatic non-small cell lung cancer (mNSCLC), hypothesizing that the use of high-dose thoracic RT with ST would increase in time and be associated with improved overall survival (OS). We identified mNSCLC patients diagnosed between 2004 and 2014 whose initial treatment comprised ST and thoracic RT (ST-RT; n = 46,315) or ST and no thoracic or extrathoracic RT (ST-only; n = 113,009). RT dose was grouped by biologically effective dose (BED10). OS was compared using multivariable regression models and propensity score (PS)–matched analyses. Median follow-up was 9.1 months and 25.8 months among those alive at last follow-up. Among ST-RT patients, 16.9% and 2.3% received BED10 70–99 Gy (n = 7806) and BED10 ≥ 100 Gy (n = 1049), respectively. Compared to the ST-only group, ST-RT patients receiving a BED10 of 40–69 Gy (HR 0.95, p < 0.001), 70–99 Gy (HR 0.69, p < 0.001), or ≥ 100 Gy (HR 0.68, p < 0.001) had improved OS on multivariable analysis, while patients receiving a BED10 of < 40 Gy (HR 1.40, p < 0.001) did not. Patients who received high-dose RT (BED10 ≥ 70 Gy; HD-RT) had improved OS compared to PS-matched controls in the ST-only group (HR 0.68, p < 0.001). Utilization of HD-RT increased year-by-year over the study period. HD-RT utilization increased and was associated with improved OS versus ST alone or ST with low-dose RT. These findings are consistent with results from recently published randomized phase II studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.